Michael A. Morse, MD, discusses key trials that have broadened the treatment landscape of mCRC, and other ongoing developments in gastrointestinal cancers.
Lilly hosted an immersive and interactive reception during the 2018 Gastrointestinal Cancers Symposium entitled,
Michael J. Overman, MD, discusses updated findings from the single-agent nivolumab CheckMate-142 cohort and combination data for nivolumab/ipilimumab from the pivotal trial.
Alpelisib (BYL719) induced a disease control rate of 58.2% and stable disease rate of 52.2% in patients with advanced solid tumors.
Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.
Older patients with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure, according to results from an analysis of the SEER database.
Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.
The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer.
Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.
Tanios Bekaii-Saab, MD, discusses the results and significance of the ReDOS study in metastatic colorectal cancer, as well as shared some insight on the Reverce trial.